Commitments and Contingencies - Additional Information (Details)									1 Months Ended		3 Months Ended	9 Months Ended	12 Months Ended
	Oct. 12, 2021 USD ($)	Oct. 06, 2021 USD ($)	Mar. 19, 2021 USD ($)	Jan. 25, 2021 USD ($)	Jan. 21, 2021 USD ($)	Jun. 05, 2020	Apr. 11, 2020 USD ($)	Sep. 27, 2017 USD ($)	Sep. 30, 2018 Patent	Aug. 31, 2016	Jun. 30, 2021 USD ($)	Sep. 30, 2021 USD ($)	Dec. 31, 2020 USD ($)	Oct. 04, 2021 USD ($)
Commitments And Contingencies [Line Items]
Reimbursement payment			$ 14,000,000.0
Minimum percentage of loan proceeds used to cover payroll costs eligible for loan forgiven						60.00%	75.00%
Gain on extinguishment of debt												$ 568,909
Other current assets												9,323,586
Pending Litigation | Piper Sandler & Co.
Commitments And Contingencies [Line Items]
Loss contingency payable fees								$ 1,100,000
Loss contingency closing date								Sep. 19, 2017
Financing aggregate consideration								$ 15,700,000
Reimbursement expenses								$ 100,000
Pending Litigation | The Securities Class Action
Commitments And Contingencies [Line Items]
Proposed settlement as a loss in accrued expenses												8,400,000
Pending Litigation | Stockholders Derivative Action
Commitments And Contingencies [Line Items]
Payment of settlement plus legal fees and costs in excess of retention (deductible) amount					$ 500,000
Other current assets												$ 900,000
PPP Loan
Commitments And Contingencies [Line Items]
Debt instrument, description												On June 5, 2020, the Payroll Protection Flexibility Act of 2020 was signed into law, adjusting certain terms of the loans issued under the PPP, including extending the initial deferral period from six to up to ten months, reducing from 75% to 60% the portion of loan proceeds required to be used to cover payroll costs, and allowing borrowers to elect a 24-week rather than an eight-week period related to employment and compensation provisions.
Gain on extinguishment of debt												$ 600,000
PPP Loan | Other Current Liabilities
Commitments And Contingencies [Line Items]
CARES act of 2020 aid loan amount													$ 400,000
PPP Loan | Other Non-current Liabilities
Commitments And Contingencies [Line Items]
CARES act of 2020 aid loan amount													$ 200,000
PPP Loan | JPMorgan Chase Bank, N.A
Commitments And Contingencies [Line Items]
CARES act of 2020 aid loan amount							$ 600,000
Promissory Note | JPMorgan Chase Bank, N.A
Commitments And Contingencies [Line Items]
Debt instrument, term							2 years
Debt instrument, interest rate							1.00%
Assistance Publique - Hopitaux de Paris ("AP-HP") | License Agreement
Commitments And Contingencies [Line Items]
Agreement entered date									2018-09
Number of patent applications | Patent									3
Assistance Publique - Hopitaux de Paris ("AP-HP") | Private Acer | License Agreement
Commitments And Contingencies [Line Items]
Agreement entered date										2016-08
Relief | Collaboration Agreement
Commitments And Contingencies [Line Items]
Upfront non-refundable payment received				$ 1,000,000.0
Cash payment received			10,000,000.0	10,000,000.0
Reimbursement payment			14,000,000.0	14,000,000.0
Repayment of outstanding balance of prior loan and interest			4,000,000.0	4,000,000.0
Development and commercial launch costs			$ 20,000,000.0
Guarantee for substantive review food and drug application				$ 0
Net profit split ratio based on territory			60.00%	60.00%
Percentage of royalty revenue received				15.00%
Milestone payment to be received			$ 6,000,000.0	$ 6,000,000.0
Promissory note cancellation amount				4,000,000.0
Relief | Collaboration Agreement | First Development Payment
Commitments And Contingencies [Line Items]
Cash payment received											$ 10,000,000.0
Development payments subject new drug application											$ 10,000,000.0
Relief | Collaboration Agreement | Second Development Payment | Subsequent Event
Commitments And Contingencies [Line Items]
Potential proceeds from development payments subject to new drug application														$ 10,000,000.0
Proceeds from first tranche of development payments subject to new drug application	$ 5,000,000.0
Relief | Collaboration Agreement | Maximum
Commitments And Contingencies [Line Items]
Development and commercial launch costs				$ 20,000,000.0
Relief | Collaboration Agreement | Secured Loan
Commitments And Contingencies [Line Items]
Debt instrument, term				12 months
Debt instrument, principal amount				$ 4,000,000.0
Debt instrument, interest rate				6.00%
Relief | Waiver and Agreement | Second Development Payment | Subsequent Event
Commitments And Contingencies [Line Items]
Potential proceeds from second tranche of development payments subject to new drug application		$ 5,000,000.0
Second tranche of development payment, expiry date		Jan. 14, 2022
Written notice period (in business days) for second tranche of development payment		15 days